Home
News
Create
Screeners
Insights
Bafna Pharmaceuticals
106.
88
-2.34
(-2.14%)
Market Cap
₹252.84 Cr
PE Ratio
-
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-2.14%
1M
-13.18%
6M
+11.61%
1Y
+45.02%
5Y
-11.16%
View Company Insights
Latest news about Bafna Pharmaceuticals
Bafna Pharmaceuticals Reports Strong Q3 FY26 Performance with 93.87% Profit Growth
Feb 11, 2026
Bafna Pharmaceuticals Limited reported strong Q3 FY26 results with revenue of ₹3,828.58 lakhs, up 15.36% YoY, and net profit of ₹183.69 lakhs, representing 93.87% growth from Q3 FY25. Nine-month performance showed revenue of ₹10,837.80 lakhs with net profit surging 193.88% to ₹835.06 lakhs. The company faces regulatory challenges including GST demands totaling ₹566.56 lakhs but remains confident of favorable outcomes through legal appeals.
Bafna Pharmaceuticals Receives Credit Rating Outlook Upgrade from ICRA Limited
Jan 23, 2026
Bafna Pharmaceuticals Reports Revenue Growth and Profit Decline in Q2 FY2026
Nov 12, 2025
Bafna Pharmaceuticals Reports Strong Q1 Results, Announces Key Leadership Changes
Aug 12, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation